Sam-A Pharm. Co., Ltd (KOSDAQ:009300)
South Korea · Delayed Price · Currency is KRW 16,310
-100 (-0.61%)
At close: Apr 21, 2026
Sam-A Pharm. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 77,799 | 95,581 | 97,211 | 81,700 | 54,666 |
Other Revenue | -0 | - | -0 | -0 | -0 |
| 77,799 | 95,581 | 97,211 | 81,700 | 54,666 | |
Revenue Growth (YoY) | -18.60% | -1.68% | 18.99% | 49.45% | 1.89% |
Cost of Revenue | 31,748 | 34,929 | 35,932 | 31,537 | 22,009 |
Gross Profit | 46,051 | 60,651 | 61,279 | 50,163 | 32,658 |
Selling, General & Admin | 26,656 | 28,367 | 29,123 | 26,661 | 20,814 |
Research & Development | 6,136 | 5,421 | 6,398 | 3,771 | 3,829 |
Amortization of Goodwill & Intangibles | 33.54 | 18.6 | 18.15 | 18.35 | 19.03 |
Other Operating Expenses | 118.33 | 113.79 | 164.66 | - | - |
Operating Expenses | 35,072 | 36,185 | 37,779 | 31,909 | 26,610 |
Operating Income | 10,979 | 24,466 | 23,500 | 18,253 | 6,048 |
Interest Expense | -441.07 | -538.22 | -219.74 | -63.43 | -125.62 |
Interest & Investment Income | 4,887 | 5,465 | 4,644 | 2,432 | 1,503 |
Earnings From Equity Investments | -863.72 | -932.85 | -915.83 | -1,290 | -2,464 |
Currency Exchange Gain (Loss) | 0 | -8.22 | -0.04 | 34.61 | 111.9 |
Other Non Operating Income (Expenses) | 543.51 | 413.63 | 390.28 | 356.41 | 236.28 |
EBT Excluding Unusual Items | 15,105 | 28,866 | 27,399 | 19,722 | 5,309 |
Gain (Loss) on Sale of Investments | 596.64 | 340.91 | 699.03 | - | 16.65 |
Gain (Loss) on Sale of Assets | 331.33 | 63.44 | 383.34 | 13.05 | 334.04 |
Asset Writedown | - | - | -5.49 | -1,335 | -325.17 |
Pretax Income | 16,033 | 29,270 | 28,476 | 18,400 | 5,335 |
Income Tax Expense | 3,093 | 7,190 | 7,102 | 6,488 | 1,943 |
Net Income | 12,940 | 22,080 | 21,374 | 11,912 | 3,392 |
Net Income to Common | 12,940 | 22,080 | 21,374 | 11,912 | 3,392 |
Net Income Growth | -41.39% | 3.30% | 79.44% | 251.22% | 2638.34% |
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 |
Shares Change (YoY) | 0.02% | -0.01% | - | - | - |
EPS (Basic) | 2120.00 | 3618.00 | 3502.01 | 1951.65 | 555.68 |
EPS (Diluted) | 2120.00 | 3618.00 | 3502.00 | 1951.65 | 555.68 |
EPS Growth | -41.40% | 3.31% | 79.44% | 251.22% | 2678.42% |
Free Cash Flow | 9,353 | 18,735 | 16,940 | 19,365 | 12,667 |
Free Cash Flow Per Share | 1532.37 | 3069.99 | 2775.59 | 3172.89 | 2075.46 |
Dividend Per Share | - | - | 750.000 | 400.000 | 250.000 |
Dividend Growth | - | - | 87.50% | 60.00% | -16.67% |
Gross Margin | 59.19% | 63.46% | 63.04% | 61.40% | 59.74% |
Operating Margin | 14.11% | 25.60% | 24.17% | 22.34% | 11.06% |
Profit Margin | 16.63% | 23.10% | 21.99% | 14.58% | 6.20% |
Free Cash Flow Margin | 12.02% | 19.60% | 17.43% | 23.70% | 23.17% |
EBITDA | 15,786 | 28,733 | 27,395 | 21,440 | 9,747 |
EBITDA Margin | 20.29% | 30.06% | 28.18% | 26.24% | 17.83% |
D&A For EBITDA | 4,808 | 4,266 | 3,895 | 3,187 | 3,699 |
EBIT | 10,979 | 24,466 | 23,500 | 18,253 | 6,048 |
EBIT Margin | 14.11% | 25.60% | 24.17% | 22.34% | 11.06% |
Effective Tax Rate | 19.29% | 24.57% | 24.94% | 35.26% | 36.43% |
Advertising Expenses | 6,603 | 7,031 | 6,787 | 5,966 | 4,174 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.